AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Stoke Therapeutics, Inc.
Video analysis: STOK
All videosNo video analysis for this stock yet. Request one from our team.
News: STOK
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Dravet.
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare C.
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK
Bank of America Corp DE lifted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) by 163.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 543,095 shares of the company's stock after buying an additional 336,931 shares during the quarter. Bank
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven.
Stoke Therapeutics' Dravet Trial Tops Enrollment Target With Zero Dropouts
Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations reported to date.
Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK
Dimensional Fund Advisors LP grew its position in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 19.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 989,936 shares of the company's stock after acquiring an additional 162,797 shares during the period. Dimensional Fund Advisors LP owned 1.59% of
Stoke Therapeutics Q2 Earnings Call Highlights
Stoke Therapeutics (NASDAQ: STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company's planned rolling new drug application submission. The global, double-blind, sham-controlled study enrolled 162 patients in 10 months, exceeding
